CATX insider filings
Perspective Therapeutics, Inc. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-11-19. Screen CATX transaction legs live →
Insider transaction summary — last 90 days
2026-08-23 to 2026-11-21, from the filings listed below: 13 insider filings (Forms 3/4/5). Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 10 legs across 8 filings by 5 insiders — 206,648 shares, $175,386 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 7 legs across 5 filings by 2 insiders — 517,889 shares, $1,622,534 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 0.
- Largest priced transaction: sale of 167,149 shares @ $3.15 ($526,051) by Lantheus Alpha Therapy, LLC, filed 2026-09-08.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Lantheus Alpha Therapy, LLC — 10% owner & Lantheus Holdings, Inc. — 10% owner | 2 | — | 3 legs · 290,061 sh · $908,166 | — |
| Lantheus Alpha Therapy, LLC — 10% owner | 1 | — | 2 legs · 113,914 sh · $357,184 | — |
| Lantheus Holdings, Inc. — 10% owner | 2 | — | 2 legs · 113,914 sh · $357,184 | — |
| Williamson Robert F III — Director | 3 | 4 legs · 64,898 sh · $53,856 | — | — |
| Spoor Johan M. — Chief Executive Officer, Director | 1 | 1 leg · 47,000 sh · $37,943 | — | — |
| Puhlmann Markus — Chief Medical Officer | 1 | 2 legs · 41,000 sh · $34,544 | — | — |
| Morich Frank — Director | 2 | 2 legs · 30,000 sh · $29,002 | — | — |
| Woods Lori A — Director | 1 | 1 leg · 23,750 sh · $20,040 | — | — |
Recent insider filings — Perspective Therapeutics, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-19 | 4 | Williamson Robert F III — Director | Purchase (P): 15,000 @ $0.80 | EDGAR |
| 2026-11-18 | 4 | Williamson Robert F III — Director | Purchase (P): 25,000 @ $0.84 | EDGAR |
| 2026-11-17 | 4 | Morich Frank — Director | Purchase (P): 15,000 @ $0.94 | EDGAR |
| 2026-11-16 | 4 | Woods Lori A — Director | Purchase (P): 23,750 @ $0.84 | EDGAR |
| 2026-11-16 | 4 | Williamson Robert F III — Director | Purchase (P): 18,609 @ $0.84 · Purchase (P): 6,289 @ $0.84 | EDGAR |
| 2026-11-16 | 4 | Morich Frank — Director | Purchase (P): 15,000 @ $1.00 | EDGAR |
| 2026-11-13 | 4 | Puhlmann Markus — Chief Medical Officer | Purchase (P): 6,000 @ $0.83 · Purchase (P): 35,000 @ $0.84 | EDGAR |
| 2026-11-12 | 4 | Spoor Johan M. — Chief Executive Officer, Director | Purchase (P): 47,000 @ $0.81 | EDGAR |
| 2026-09-08 | 4 | Lantheus Alpha Therapy, LLC — 10% owner Lantheus Holdings, Inc. — 10% owner | Sale (S): 80,783 @ $3.11 · Sale (S): 167,149 @ $3.15 | EDGAR |
| 2026-09-04 | 4 | Lantheus Alpha Therapy, LLC — 10% owner Lantheus Holdings, Inc. — 10% owner | Sale (S): 42,129 @ $3.11 | EDGAR |
| 2026-09-04 | 4 | Lantheus Alpha Therapy, LLC — 10% owner | Sale (S): 78,145 @ $3.14 · Sale (S): 35,769 @ $3.12 | EDGAR |
| 2026-09-03 | 4 | Lantheus Holdings, Inc. — 10% owner | Sale (S): 35,769 @ $3.12 | EDGAR |
| 2026-09-02 | 4 | Lantheus Holdings, Inc. — 10% owner | Sale (S): 78,145 @ $3.14 | EDGAR |
| 2026-03-04 | 4 | Puhlmann Markus — Chief Medical Officer | Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2026-03-04 | 4 | Martinez Maria E — Director | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2026-03-04 | 4 | Morich Frank — Director | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2026-03-04 | 4 | Spoor Johan M. — Chief Executive Officer, Director | Grant/award (A): 735,000 (derivative) @ $0 | EDGAR |
| 2026-03-04 | 4 | Williamson Robert F III — Director | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2026-03-04 | 4 | Woods Lori A — Director | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2026-03-04 | 4 | Hunt Jonathan Robert — Chief Accounting Officer | Grant/award (A): 90,000 (derivative) @ $0 | EDGAR |
| 2026-03-04 | 4 | HENSON HEIDI — Director | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2025-11-17 | 4 | Hunt Jonathan Robert — Chief Accounting Officer | Purchase (P): 11,000 @ $2.03 | EDGAR |
| 2025-11-14 | 4 | Williamson Robert F III — Director | Purchase (P): 9,498 @ $2.10 | EDGAR |
| 2025-09-05 | 4 | Martinez Maria E — Director | Grant/award (A): 75,000 (derivative) @ $0 | EDGAR |
| 2025-09-05 | 4 | Sendek Joel — Chief Financial Officer | Grant/award (A): 600,000 (derivative) @ $0 | EDGAR |
| 2025-04-01 | 4 | Graham Juan — Chief Financial Officer | Purchase (P): 33,333 @ $2.25 | EDGAR |
| 2025-04-01 | 4 | Spoor Johan M. — Chief Executive Officer, Director | Purchase (P): 22,026 @ $2.24 · Purchase (P): 4,650 @ $2.21 | EDGAR |
| 2025-04-01 | 4 | Williamson Robert F III — Director | Purchase (P): 22,192 @ $2.27 · Purchase (P): 38,145 @ $2.14 | EDGAR |
| 2025-04-01 | 4 | Woods Lori A — Director | Purchase (P): 23,475 @ $2.13 | EDGAR |
| 2025-03-05 | 4 | Puhlmann Markus — Chief Medical Officer | Grant/award (A): 165,000 (derivative) @ $0 | EDGAR |
| 2025-03-05 | 4 | Morich Frank — Director | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2025-03-05 | 4 | Spoor Johan M. — Chief Executive Officer, Director | Grant/award (A): 650,000 (derivative) @ $0 | EDGAR |
| 2025-03-05 | 4 | Williamson Robert F III — Director | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2025-03-05 | 4 | Woods Lori A — Director | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2025-03-05 | 4 | Hunt Jonathan Robert — Chief Accounting Officer | Grant/award (A): 75,000 (derivative) @ $0 | EDGAR |
| 2025-03-05 | 4 | HENSON HEIDI — Director | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2025-01-07 | 4 | Graham Juan — Chief Financial Officer | Grant/award (A): 400,000 (derivative) @ $0 | EDGAR |
| 2024-12-06 | 4 | HENSON HEIDI — Director | Purchase (P): 25,975 @ $3.85 | EDGAR |
| 2024-12-04 | 4 | Spoor Johan M. — CEO, Director | Purchase (P): 8,000 @ $3.77 | EDGAR |
| 2024-12-04 | 4/A | Spoor Johan M. — CEO, Director | Holdings only — no transactions reported | EDGAR |
| 2024-12-04 | 4/A | Williamson Robert F III — Director | Holdings only — no transactions reported | EDGAR |
| 2024-11-27 | 4 | Williamson Robert F III — Director | Purchase (P): 3,647 @ $3.62 · Purchase (P): 2,619 @ $3.67 | EDGAR |
| 2024-11-27 | 4 | Hunt Jonathan Robert — Chief Financial Officer | Purchase (P): 400 @ $3.55 · Purchase (P): 29 @ $3.94 · Purchase (P): 2,400 @ $3.60 · Purchase (P): 10,000 @ $3.88 | EDGAR |
| 2024-11-26 | 4 | Spoor Johan M. — CEO, Director | Purchase (P): 14,500 @ $3.78 · Purchase (P): 5,400 @ $3.80 · Purchase (P): 6,600 @ $3.80 | EDGAR |
| 2024-07-19 | 4 | Austin Mark John — VP Finance/Prin Fin&Acct Offic | Grant/award (A): 34,500 (derivative) @ $0 | EDGAR |
| 2024-06-24 | 4 | Spoor Johan M. — CEO, Director | Grant/award (A): 500,000 (derivative) @ $0 | EDGAR |
| 2024-06-24 | 4 | Williamson Robert F III — Director | Grant/award (A): 23,000 (derivative) @ $0 | EDGAR |
| 2024-06-24 | 4 | Woods Lori A — Director | Grant/award (A): 23,000 (derivative) @ $0 | EDGAR |
| 2024-06-24 | 4 | Hunt Jonathan Robert — Chief Financial Officer | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2024-06-24 | 4 | HENSON HEIDI — Director | Grant/award (A): 23,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — Perspective Therapeutics, Inc.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-11-09 | 8-K | 2.02 — Results of Operations and Financial Condition 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-11-06 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-11-06 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-10-23 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-10-08 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-10-01 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-14 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-08 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-10 | 8-K | 2.02 — Results of Operations and Financial Condition 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-03 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=CATX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs